Adolescents and adults aged 12 years to75 years with a diagnosis of atopic dermatitis (AD), may qualify to participate. Individuals must have Moderate to Severe AD with involvement of 10% or more body surface area (BSA). A history of AD with at least 6 months history of inadequate response to topical AD medications, or have required systemic treatment for control of disease
Participants will receive investigational topical medication (active study drug) or placebo, via a cream. Study medication and study-related care will be provided at no cost. Reimbursement for study-related expenses will also be provided.
Study participation will last about 8 weeks and involve about 5 visits to the study centre.